Search results
Showing 851 to 900 of 4138 results for patient
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)
Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage 3 melanoma in adults.
Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.
could have conventional cardiac pacemaker implantation should report the patient selection criteria and compare leadless pacemakers with...
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.
Digitally enabled therapies for adults with anxiety disorders: early value assessment (HTG676)
Early value assessment (EVA) guidance on digitally enabled therapies for adults with anxiety disorders.
for treating and preventing migraine. Data should be collected for all patients not entered into controlled trials. Studies should...
Neuropad for detecting preclinical diabetic peripheral neuropathy (HTG486)
Evidence-based recommendations on Neuropad for detecting preclinical diabetic peripheral neuropathy.
Evidence-based recommendations on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults.
Canagliflozin in combination therapy for treating type 2 diabetes (TA315)
Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes in adults.
Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)
This guideline sets out an antimicrobial prescribing strategy for managing and preventing acute exacerbations of bronchiectasis (non-cystic fibrosis). It aims to optimise antibiotic use and reduce antibiotic resistance.
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer (TA1014)
Evidence-based recommendations for the adjuvant treatment of ALK-positive non-small-cell lung cancer in adults.
Show all sections
Methadone and buprenorphine for the management of opioid dependence (TA114)
Evidence-based recommendations on methadone and buprenorphine (oral formulations) for managing opioid dependence in adults.
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)
Evidence-based recommendations on cabozantinib (Cabometyx) with nivolumab (Opdivo) for untreated advanced renal cell carcinoma in adults.
Evidence-based recommendations on AposHealth for knee osteoarthritis.
Palforzia for treating peanut allergy in children and young people (TA769)
Evidence-based recommendations on Palforzia for treating peanut allergy in children and young people.
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)
Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by narcolepsy in adults.
Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.
One-piece closed bags for colostomies: late-stage assessment (HTG754)
Late stage assessment (LSA) guidance on one-piece closed bags for colostomies
View recommendations for HTG754Show all sections
Devices for remote monitoring of Parkinson's disease (HTG657)
Evidence-based recommendations on Kinesia 360 and KinesiaU (Great Lakes NeuroTechnologies), PDMonitor (PD Neurotechnology), Personal KinetiGraph (Global Kinetics) and STAT-ON (Sense4care) for remote monitoring of Parkinson’s disease.
Pulmonary artery pressure technologies for remote monitoring of chronic heart failure
In development Reference number: GID-DG10087 Expected publication date: 05 February 2026
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma (TA677)
Evidence-based recommendations on brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton’s tyrosine kinase (BTK) inhibitor.
Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.
Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)
Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.
Immunosuppressive therapy for kidney transplant in adults (TA481)
Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in adults. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).
Medical technologies evaluation programme process guide (PMG34)
This process guide describes how NICE selects medical technologies for development of NICE guidance. It also describes how the medical technologies advisory committee develops guidance on selected technologies routed to it
Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.
Guidance on the use of patient-education models for diabetes (TA60)
This guidance has been replaced by NICE guideline NG17.
Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults.
Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures in adults.
Evidence-based recommendations on lumasiran (Oxlumo) for primary hyperoxaluria type 1 in people of all ages.
This guideline covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care.
Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (HTG607)
Evidence-based recommendations on Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care.
Evidence-based recommendations on new generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners.
used in the context of research. Research studies should clearly define patient selection, and outcomes should include measures of...
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)
Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia in adults.
Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)
Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children.
Aflibercept for untreated retinopathy in babies born preterm TS ID 11943
Topic prioritisation
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee
Evidence-based recommendations on latanoprost–netarsudil (Roclanda) for previously treated primary open-angle glaucoma or ocular hypertension in adults.
Endocuff Vision for assisting visualisation during colonoscopy (HTG514)
Evidence-based recommendations on Endocuff Vision for assisting visualisation during colonoscopy.
using a biodegradable scaffold. This should include clear descriptions of patient selection and adjunctive treatments. Outcome measures...
Medical technologies evaluation programme methods guide (PMG33)
This methods guide describes how NICE selects medical technologies for development of NICE guidance. It also describes how the medical technologies advisory committee develops guidance on selected technologies routed to it
Asfotase alfa for treating paediatric-onset hypophosphatasia (HST23)
Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in babies, children, young people and adults.
Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making
including observational data collection. Studies should clearly define patient selection. Outcomes should include completeness of...
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648) [ID6480]
In development Reference number: GID-TA11630 Expected publication date: TBC
In development Reference number: GID-TA11519 Expected publication date: 12 June 2026